Image For Activity Cover
The Lead Episode 56: Durability of Pulmonary Vein Isolation Using Pulsed-Field Ablation

William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by guest Amin Al-Ahmad, MD, FHRS, CCDS, Texas Cardiac Arrhythmia Institute and Jorge Romero, Jr., MD, FHRS, Brigham and Women's Hospital to discuss how Pulsed-field ablation (PFA) is a novel nonthermal ablation technology with high procedural safety and efficiency for pulmonary vein isolation (PVI). Premarket data showed high PVI durability during mandatory remapping studies. Data on lesion durability in real-world patients with clinically indicated redo procedures are scarce. In this episode of The Lead, we discuss why and how this study sought to report PVI durability rates in patients undergoing a clinically indicated redo procedure after an index PVI using PFA.

Learning Objectives
  • To discuss the study, "Durability of Pulmonary Vein Isolation Using Pulsed-Field Ablation," and it's objectives, methods, results, conclusions, and limitations. 
Article Authors and Podcast Contributors
Article Authors
Thomas Kueffer, MSC, Stefano Bordignon, MD, Kars Neven, MD, PHD, Yuri Blaauw, MD, Jim Hansen, MD, Raquel Adelino, MD, Alexandre Ouss, MD, Anna Füting, MD, Laurent Roten, MD, Bart A. Mulder, MD, PHD, Martin H. Ruwald, MD, PHD, Roberto Mené, MD, Pepijn van der Voort, MD, Nico Reinsch, MD, Serge Boveda, MD, PHD Elizabeth M. Albrecht, PHD, Christopher W. Schneider, MSC, K.R. Julian Chun, MD, Boris Schmidt, MD, Tobias Reichlin, MD

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital
Amin Al-Ahmad, MD, FHRS, CCDS, Texas Cardiac Arrhythmia Institute
Jorge Romero, Jr., MD, FHRS, Brigham and Women's Hospital
Disclosure Policy

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.


Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers


All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic

Contributor Disclosure(s):
A. Al-Ahmad: Honoraria/Speaking/Consulting: Abbott, Biosense Webster, Inc., Boston Scientific, Haemonetics, Mediasphere Medical, Medtronic, Philips, Stocks, Privately Held: Soundcath
J. Romero: Honoraria/Speaking/Consulting: Sanofi, Boston Scientific, AtriCure, Inc.

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
© Heart Rhythm Society
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
Android App Download IOS App Download Powered By